EFPIA

Promotional information should not imitate the devices, copy, slogans or general layout adopted by other manufacturers in a way that is likely to mislead or confuse. 

Promotional information should not imitate the devices, copy, slogans or general layout adopted by other manufacturers in a way that is likely to mislead or confuse. Promotional information must not infringe or be able to infringe intellectual property rights, trademarks, patents or similar rights of other person or entity. 

---

The European Federation of Pharmaceutical Industries and Associations (EFPIA) The Pharmaceutical Research and Manufacturers of America (PhRMA)... 

Good Manufacturing Practice for Active Ingredient Manufacturers , 1996, CEFIC-EFPIA, August. 

European Federation of Pharmaceutical Industries and Associations (EFPIA)... 

The EFPIA is situated in Brussels and has, as its members, 25 national pharmaceutical industry associations and leading pharmaceutical companies. Much of the Federation s work is concerned with the activities of the European Commission and the new EMEA. 

There are six parties directly involved in ICH as well as observers and the International Federation of Pharmaceufical Manufacturers Association (IFPMA see Table 25.1). The six parties are the founder members of ICH, and fhey represenf fhe regulatory bodies and the research-based industry in the European Union (EU), Japan, and the United States in the EU, the European Federation of Pharmaceufical Indusfries and Associations (EFPIA) and the Ministry of Healfh, Labour, and Welfare (MHLW) in Japan, the Japan Pharmaceutical Manufacturers Association (JPMA) and in the United States, the FDA and the Pharmaceutical Researchers and Manufacturers of America (PhRMA). 

Founded in 1990, the International Conference on Harmonization (ICH) is comprised of the pharmacopeial manufacturers associations in Europe (EFPIA), Japan (JPMA), the United States (PMA), and the drug regulatory agencies in Europe (EEC), Japan (MHW), and the United States (FDA), with the International Federation of Pharmaceutical Manufacturers Association (IFPMA) serving as secretariat. Pharmacopeias are not members of the ICH, where membership is reserved for three PMAs and three regulatory agencies. Invited observers include Canada, WHO, and the European Free Trade Association (EFTA). 

European Federation of Pharmaceutical Industries Associations. European Code of Practice for the Promotion of Medicines, 2nd edn. Brussels EFPIA, 1992. 

A Guideline on the Readability of the Label and Package Eeaflet of Medicinal Products for Human Use. Brussels EFPIA, 1998. 

Following extensive discussions among aU interested parties, such as the national authorities, the EC and the European Federation of Pharmaceutical Industries and Associations (EFPIA), the EC proposed comprehensive reform of the EU pharmaceutical legislation. The amending legislations are ... 

EFPIA European Code of Practice for the Promotion of Medicines... 

European Federation of Pharmaceutical Industries and Associations (EFPIA) With EFPIA membership from sixteen countries in Western Europe, including all of Europe s major research-based pharmaceutical companies, the Federation s work is concerned with the activities of the EMEA. A wide network of experts and country coordinators has been established to ensure that EFPIA s views are represented in ICH guidelines. 

A second workshop was organized in The Netherlands (November 19 21, 2003) by the International Pharmaceutical Federation (FIP). This was in collaboration with FDA, EMEA, and other European trade and professional associations (EFPIA, EUFEPS, APIC/CEFIC and IPEC) http // www.qualityworkshop.nl/html/welkom.html. 

One of the key elements for its success is most probably the composition of the organization. It was founded in 1990 as a joint regulatory/industry initiative. The six cosponsors are the EC and the EFPIA (European Federation of Pharmaceutical Industries Association) for the EU, the MHLW and JPMA (Japan Pharmaceutical Manufacturers Association) for Japan, and the U.S. FDA and PhRMA (Pharmaceutical Research and Manufacturers of America) for the United States. 

OECD, EFPIA. 2005. Pharmaceutical associations of the European countries, VFA. The Pharmaceutical Production Worldwide Report. Available at http //www.vfa.de/en/articles/index-en.html. 

EFPIA Innovative medicine for Europe. EFPIA, Brussels, 2004. 

To quote The European Federation of Pharmaceutical Industries and Associations (EFPIA) Policy Statement on the use of animals in research and development, as our biological knowledge increases, so too does the usefulness of nonanimal methods. There are still enormous gaps in our biological knowledge that limit the usefulness of cell culture and computer based research . 

The International Conferences was jointly supported and organized by the Commission of the European Communities (CEC), the US Food and Drug Administration (FDA), the Japanese Ministry of Health and Welfare (MHW), together with the pharmaceutical industry, as represented by the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), the European Federation of Pharmaceutical Industry Associations (EFPIA), the US Pharmaceutical Manufacturers Association (PMA) and the Japanese Pharmaceutical Manufacturers Association (PMA). 

A Steering Committee was appointed with members from EU, FDA, MHW, EFPIA, JPMA, PMA and IFPMA, with observers from WHO, and from the regulatory authorities of Canada and Switzerland (for... 

He is currently a member of the Task Force General/Safety Pharmacology Ger-man/Swiss Pharmaceutical Companies, Safety ad hoc Group EFPIA. He served several times as a member of the program committee of the S afety Pharmacology Society. He is member of several domestic and international scientific societies. 

EFPIA European Federation of Pharmaeeutieal Industry Association... 

ICH 1, the first international ICH meeting, was held in Brussels in November of 1991. This meeting, sponsored by the Commission of the European Communities and the European Federation of Pharmaceutical Industries Associations (EFPIA), was composed of three parallel workshops on the topics of Quality, Safety, and Efficacy and identified 11 topics for harmonization. 

Recipients were requested to propose the level of exposure in terms of energy output. Inclusion of an approximate relationship between this and real exposures would be welcomed" for all three of these options. The JPMA proposed a 24-hour exposure time for part 2 of Option 1. The EFPIA suggested an exposure time of 24 hours for Option 2 (no irradiance/illumination level given) while the JPMA suggested and overall illumination of 10 lux hours, considered equivalent "to 90 days average exposure." The maximum energy emission of the UV-A lamp was widened in this draft to now include 350 nm, for a new specification of "between 350 and 370 nm". 

---